How Scientists Tested Teplizumab Before It Reached Patients

Teplizumab is a monoclonal antibody—a type of protein designed to target specific cells in the immune system. This drug is engineered to bind to CD3, a protein found on T cells, which are white blood cells involved in the immune response. By binding to CD3, teplizumab works to delay the onset of clinical Type 1 diabetes in people at high risk. It is important to note that teplizumab delays the disease; it is not a cure.

The drug was approved based on clinical evidence showing it could extend the time before Type 1 diabetes symptoms appear in at-risk individuals. Understanding how this drug was tested before reaching patients provides valuable insight into modern immunotherapy development.

Before any new drug is given to people, researchers must conduct extensive testing in laboratory animals. However, teplizumab presented an unusual problem: the drug is designed to bind to human CD3, but it does not naturally bind to CD3 in commonly used research animals like mice. This mismatch made it impossible to test the drug directly in its human form.

To solve this problem, scientists created a mouse surrogate—essentially a modified version of teplizumab that could bind to mouse CD3 while maintaining the same basic structure and function. The mouse surrogate had a binding affinity to mouse CD3 of 3.0 μM, while the original teplizumab had a binding affinity to human CD3 of 2.3 μM. These similar binding strengths suggested the surrogate would behave much like the human version in laboratory studies.

Researchers tested the mouse surrogate in prediabetic nonobese diabetic mice, a standard model for studying Type 1 diabetes. The results were encouraging: mice treated with the mouse surrogate showed delayed diabetes onset and a 30% reduction in diabetes incidence compared to untreated control mice.

Safety testing revealed that the drug primarily affected T lymphocytes, a type of white blood cell targeted by the drug's mechanism. Importantly, researchers found no effects on fertility, reproductive performance, or embryo-fetal development at most dose levels. However, reduced fertility was noted in the next generation of mice exposed to the highest maternal doses, indicating a dose-dependent effect that researchers continue to monitor.

The strategy used to develop and test teplizumab—creating a species-specific surrogate antibody—addressed a real gap in drug development. Many monoclonal antibodies face similar crossreactivity challenges, meaning they don't naturally bind to target proteins in common research animals.

By demonstrating that a surrogate-based approach could generate meaningful preclinical data on pharmacology, toxicology, and safety, this research provides a blueprint for developing other monoclonal antibodies that lack natural crossreactivity with animal models. This could accelerate the path from laboratory discovery to clinical testing for future immunotherapies and make drug development more efficient across the field.

Source: The Journal of pharmacology and experimental therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.